

**Supplementary table 1.** Demographic, reproductive and clinical variables among women from the two included sub-studies. Data presented as n (%) or median (interquartile range).

	Substudy 1 <sup>a</sup> (n = 118)	Substudy 2 <sup>b</sup> (n = 184)	p
Age			0.001
< 20 years, n (%)	1 (0.8)	15 (8.2)	
20-24 years, n (%)	50 (42.4)	82 (44.6)	
25-29 years, n (%)	60 (50.8)	62 (33.7)	
>30 years, n (%)	7 (5.9)	25 (13.6)	
Parous, n (%)	6 (5.1)	18 (9.8)	0.141
Induced abortion, n (%)	10 (8.5)	27 (14.7)	0.109
Repeated induced abortion, n (%)	3 (2.5)	9 (4.9)	0.378
BMI			0.906
<18.5 kg/m <sup>2</sup> , n (%)	9 (7.6)	12 (6.5)	
18.5 – 24.99 kg/m <sup>2</sup> , n (%)	97 (82.2)	149 (81)	
25.0 – 29.99 kg/m <sup>2</sup> , n (%)	10 (8.5)	20 (10.9)	
>30 kg/m <sup>2</sup> , n (%)	2 (1.7)	3 (1.6)	
Smoking, n (%)	9 (7.6)	14 (7.8)	0.962
Educational years, mean ± SD	14.94 ± 2.1	14.81 ± 2.2	0.604
Age of start of contraceptive use, median (IQR)	-	16 (15 -18)	
Duration of HC use, months, mean ± SD	40 ± 35	55 ± 41	0.008
Previous use of more than 2 CHCs, n (%)	20 (16.9)	25 (13.6)	0.423
Previous use of LNG-containing pill, n (%)	96 (81.4)	121 (65.8)	0.003
Previous use of anti-androgenic pill, n (%)	51 (43.2)	59 (32.1)	0.049
Migraine, n (%)	12 (10.2)	5 (2.7)	0.006
Dysmenorrhea or endometriosis, n (%)	21 (17.8)	25 (13.6)	0.321

<sup>a</sup> = the cross-sectional study, carried out in 2007. <sup>b</sup> = the randomised controlled trial, carried out in 2013-2015.

Percentages given in relation to available responses, missing values in 1.0 – 2.6% of cases. BMI = Body Mass Index; CHC = Combined hormonal contraceptive; CI = confidence interval; HC = hormonal contraceptive; IQR = interquartile range; LNG = levonorgestrel; SD = standard deviation.

Anti-androgenic pills contain either drospirenone, cyproterone acetate or desogestrel.

P-values according to chi-square test or, in case of less than five values, Fisher's Exact test.